In our patients with PsA, the most commonly prescribed DTT was anti-IL17 plus anti-TNF with a high efficacy rate (80% MCI) which suggests that this combination deserves more research as we have found only a case report on this DTT, which proved unsuccessful due to psoriasis activity (27). The gene discussed is IL17A; the disease is psoriasis.